ALCOVE
Energy Environment
ALCOVE project : Redefining Lung Cancer Screening Through Breath Analysis. INTERREG France – Wallonia – Flanders
The INTERREG ALCOVE project, coordinated by Lille University Hospital (CHU de Lille), aims to improve lung cancer screening in the cross-border area of France – Wallonia – Flanders, through a coordinated, multidisciplinary and innovative approach.
Project Objectives
The long-term goal of the ALCOVE project is to offer a new, non-invasive and fast tool to redefine the lung cancer screening pathway by:
- Testing the use of an electronic nose by healthcare professionals as a new tool for medical dialogue
- Evaluating the electronic nose’s ability to detect the potential risk of lung cancer
- Facilitating communication between at-risk populations and the healthcare system
- Involving patients, healthcare professionals and institutions in a co-construction process
The ambition is to enable earlier diagnosis, better patient care, and optimized use of available resources.
Why is ALCOVE essential?
A major public health issue
A concrete impact on the territory
ALCOVE addresses three key challenges for the future of screening:
- Tackling low participation rates in screening programs
- Testing a miniaturized electronic nose in real hospital settings
- Proposing a reproducible and transferable model beyond the cross-border region
A coordinated cross-border approach
What ALCOVE will deliver:
- A simple, clinically validated screening tool for primary care professionals
- Shared data and indicators to guide public health policies for organized lung cancer screening
- A transferable screening model for use in other regions
- Stronger engagement from professionals, institutions, and patients
What is the contribution of IMT Nord Europe?
As part of this project, the CERI EE teams aim to enhance the response of the electronic nose by supplying new sensors based on conductive polymers. In this way, the centre’s expertise in the metrology and development of gas sensors, initially dedicated to air quality, is being applied to biomedical issues relating to the early detection of lung cancer.
Project Start: October 1, 2024
Duration: 4 years
Budget: €6.6 million
Coordinator: CHU Lille (France)
Partners: ULiège (Wallonie), Umons (Wallonie), ULille (France), IMT Nord Europe (France), Materia Nova (Wallonie), Eurasanté (France), CHU Amiens Picardie (France), CHU Reims (France), Groupe Hospitalier Artois Ternois (France), KU Leuven (Flandre), Université de Reims Champagne-Ardenne (France), CHU HELORA (Wallonie), U.B Institut Jules Bordet (Bruxelles), UZGent (Flandre), CHU de Namur (Wallonie), UZ Leuven (Flandre)
Stay updated on the project:
- On LinkedIn: ALCOVE – Redéfinir le dépistage du cancer du poumon I De screening op longkanker herdefiniëren
- On the project website: www.alcove.crosss3.eu
Want to learn more about
"ALCOVE" ?
Our teams at the IMT Nord Europe research centres are here to help
CONTACT US